

See IGIV in a different light.



Product Specifics	Bayer Gamunex® ¹ Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified	Baxter Gammagard® S/D ² Immune Globulin Intravenous (Human)	American Red Cross Polygam® S/D ³ Immune Globulin Intravenous (Human)	ZLB Behring Carimune® NF Nanofiltered* ⁴ Immune Globulin Intravenous (Human)	ZLB Behring Gammar®-P I.V. ⁵ Immune Globulin Intravenous (Human)	Grifols Flebogamma® 5% ⁶ Immune Globulin Intravenous (Human)	Octapharma Octagam® ⁷ Immune Globulin Intravenous (Human)
Form	Liquid	Lyophilized	Lyophilized	Lyophilized	Lyophilized	Liquid	Liquid
Indications	PID, ITP	PID, ITP, CLL, Kawasaki syndrome	PID, ITP, CLL, Kawasaki syndrome	Immunodeficiency, ITP	Primary defective antibody synthesis	PID	PID
Contraindications	Selective IgA deficiencies with known antibody against IgA	Selective IgA deficiency where the IgA deficiency is the only abnormality of concern	Selective IgA deficiency where the IgA deficiency is the only abnormality of concern	Selective IgA deficiency/ antibody to IgA	Isolated IgA deficiency	Selective IgA deficiency/ and demonstrable antibodies to IgA	Selective IgA deficiency/ IgE mediated antibodies to IgA
IgA Content	Average of 46 µg/mL	≤2.2 µg/mL in a 5% solution	≤2.2 µg/mL in a 5% solution	720 µg/mL ⁸	<25 µg/mL ⁸	<50 µg/mL	≤0.1 mg/mL in a 5% solution
IgG Content	Distribution of subclasses similar to that in normal human plasma	Distribution of subclasses similar to that in normal human plasma	Distribution of subclasses similar to that in normal human plasma	Distribution of subclasses similar to that in normal human plasma	Distribution of subclasses similar to that in normal human plasma	Distribution of subclasses similar to that in normal human plasma	Distribution of subclasses similar to that in normal human plasma
IgM Content	≤.002 g/L	Trace amounts	Trace amounts	Trace amounts	<25 µg/mL ⁸	Trace amounts	≤0.1 mg/mL
Sugar Content	No sugar	20 mg/mL glucose in a 5% solution	20 mg/mL glucose in a 5% solution	1.67 g sucrose per g protein	5% sucrose	50 mg/mL D-sorbitol	100 mg/mL maltose
Sodium Content	Trace amounts	Approximately 8.5 mg/mL sodium chloride	Approximately 8.5 mg/mL sodium chloride	<20 mg sodium chloride per g protein	0.5% sodium chloride	<3.2 mEq/L (<0.02%) ⁹	≤30 mmol/L
Viral Inactivation/ Removal Processes	Caprylate precipitation/Cloth filtration; Caprylate incubation; Column chromatography; Final container low pH incubation	Cold ethanol fractionation; Solvent detergent	Cold ethanol fractionation; Solvent detergent	Cold ethanol fractionation; at acid pH 4 in presence of pepsin; Nanofiltration	Cold alcohol fractionation; Pasteurization at 60°C for 10 hours	Cold alcohol fractionation Polyethylene glycol precipitation; Ion exchange chromatography; Heat pasteurization	Cold ethanol fractionation; ultrafiltration; chromatography Solvent detergent; pH 4 treatment
pH When Liquid	4.0–4.5	6.8±0.4	6.8±0.4	6.6±0.2	6.8±0.4	5.0–6.0	5.1–6.0
Osmolality/Osmolarity	258 mOsm/kg	636 mOsm/L (5%) ⁸ 1250 mOsm/L (10%) ⁸	636 mOsm/L (5%) ⁸ 1250 mOsm/L (10%) ⁸	384 mOsm/kg (6%) [†] 768 mOsm/kg (12%) [†]	309 mOsm/L (5%) ⁸ 600 mOsm/L (10%) ⁸	240–350 mOsm/L	310–380 mOsm/kg
Maximum Infusion Rate	0.08 mL/kg/min	4 mL/kg/hr (5%) 8 mL/kg/hr (10%)	4 mL/kg/hr (5%) 8 mL/kg/hr (10%)	See P.I.	0.03–0.06 mL/kg/min	0.10 mL/kg/min	0.07 mL/kg/min
Time to Infuse 35 g [‡]	1.0 hour [§]	2.5 hours (5%) [§] 0.6 hour (10%) [§]	2.5 hours (5%) [§] 0.6 hour (10%) [§]	<3.3 hours (6% solution) ⁹	2.8 hours ⁹	1.67 hours	2.4 hours
Reconstitution Time	Liquid/ready-to-use	<5 minutes at room temperature; >20 minutes if cold [§]	Within minutes [§]	Several minutes, though in exceptional cases, may take up to 20 minutes	<20 minutes	Liquid/ready-to-use	Liquid/ready-to-use
Storage Requirements	Room temperature, not to exceed 25°C (77°F) for up to 5 months [§] ; 2°–8°C for 36 months (36°–46°F); Do not freeze	Room temperature, not to exceed 25°C (77°F); Do not freeze	Room temperature, not to exceed 25°C (77°F); Do not freeze	Room temperature, not to exceed 30°C (86°F); Do not freeze solution	Room temperature, not to exceed 25°C (77°F); Do not freeze	Room temperature, 2°–25°C (36°–77°F); Do not freeze	Room temperature, not to exceed 25°C (77°F) for up to 18 months from date of manufacture; 2°–8°C (36°–46°F) for 24 months

*Formerly named ZLB Bioplasma I.G.I.V.

†Depends on diluent used.

‡0.5 g/kg for 70 kg adult = 35 g; 5% Concentrations: 1 g = 20 mL; 10% Concentrations: 1 g = 10 mL. The time to infuse is based on the maximal infusion rate.

§During first 18 months from date of manufacture.

IMPORTANT NOTICE—The information provided herein is a summary of available information only. This summary is to be used as a general educational tool and is not intended for use as a guideline for clinical evaluations. Such evaluations (including, but not limited to, initial and/or subsequent dosing, conversions from specific product brands, etc) should utilize a thorough review of appropriate clinical data. Product package inserts are the primary source of information. Additional sources of information are noted.

Please see full Prescribing Information before prescribing.